Autoantibodies to Tumor-associated Antigens As Biomarkers in Cancer Immunodiagnosis

Overview

Journal Autoimmun Rev

Publisher Elsevier

Specialty Allergy & Immunology

Date 2010 Dec 21

PMID 21167321

Citations 42

Authors

Weihong Liu

Bo Peng

Yumin Lu

Weijia Xu

Wei Qian

Jian-Ying Zhang

Affiliations

Soon will be listed here.

Abstract

Cancer sera contain antibodies that react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs), and therefore these autoantibodies can be considered as reporters from the immune system, to identify authentic TAAs involved in the malignant transformation. Once a TAA is identified, different approaches would be used to comprehensively characterize and validate the identified TAA/anti-TAA systems that are potential biomarkers in cancer immunodiagnosis. In this manner, several novel TAAs such as p62 and p90 have been identified in our previous studies. p62, a member of IGF-II mRNA binding proteins (IMPs), is an oncofetal protein absent in adult tissues, the presence of anti-p62 autoantibodies relates to abnormal expression of p62 in tumor cells. p90 was recently characterized as an inhibitor of the tumor suppressor PP2A (protein phosphatase 2A), and an autoantibody to p90 appears in high frequency in prostate cancer. The present review will focus on the recent advances in studies mainly associated with these two novel TAAs as biomarkers in cancer immunodiagnosis.

Citing Articles

Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.

Montero-Calle A, Garranzo-Asensio M, Moreno-Casbas M, Campuzano S, Barderas R Front Immunol. 2024; 15:1455602.

PMID: 39234247 PMC: 11371560. DOI: 10.3389/fimmu.2024.1455602.

Anti-BIRC5 autoantibody serves as a valuable biomarker for diagnosing AFP-negative hepatocellular carcinoma.

Li Q, Liu H, Wang H, Xiong W, Dai L, Zhang X PeerJ. 2024; 12:e17494.

PMID: 38832035 PMC: 11146321. DOI: 10.7717/peerj.17494.

Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.

Cheng Y, Li Q, Sun G, Li T, Zou Y, Ye H Sci Rep. 2024; 14(1):9757.

PMID: 38684875 PMC: 11058243. DOI: 10.1038/s41598-024-60544-2.

A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma.

Li T, Xia J, Yun H, Sun G, Shen Y, Wang P Cancer Cell Int. 2023; 23(1):273.

PMID: 37974212 PMC: 10655307. DOI: 10.1186/s12935-023-03107-1.

Identification of novel serum autoantibody biomarkers for early esophageal squamous cell carcinoma and high-grade intraepithelial neoplasia detection.

Chen Z, Xing J, Zheng C, Zhu Q, He P, Zhou D Front Oncol. 2023; 13:1161489.

PMID: 37251926 PMC: 10213680. DOI: 10.3389/fonc.2023.1161489.

References

Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X . CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009; 15(16):5092-100. DOI: 10.1158/1078-0432.CCR-08-3283. View

Vainer G, Vainer-Mosse E, Pikarsky A, Shenoy S, Oberman F, Yeffet A . A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation. J Pathol. 2008; 215(4):445-56. PMC: 3148580. DOI: 10.1002/path.2376. View

Zhang J, Chan E, Peng X, Tan E . A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med. 1999; 189(7):1101-10. PMC: 2193003. DOI: 10.1084/jem.189.7.1101. View

CRAWFORD L, Pim D, Bulbrook R . Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982; 30(4):403-8. DOI: 10.1002/ijc.2910300404. View

Junttila M, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T . CIP2A inhibits PP2A in human malignancies. Cell. 2007; 130(1):51-62. DOI: 10.1016/j.cell.2007.04.044. View

Bates P, Fisher R, Ward A, Richardson L, Hill D, Graham C . Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer. 1995; 72(5):1189-93. PMC: 2033962. DOI: 10.1038/bjc.1995.484. View

Keene J . Why is Hu where? Shuttling of early-response-gene messenger RNA subsets. Proc Natl Acad Sci U S A. 1999; 96(1):5-7. PMC: 33538. DOI: 10.1073/pnas.96.1.5. View

Imai H, Chan E, Kiyosawa K, Fu X, Tan E . Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest. 1993; 92(5):2419-26. PMC: 288425. DOI: 10.1172/JCI116848. View

Janssens V, Goris J, Van Hoof C . PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 2005; 15(1):34-41. DOI: 10.1016/j.gde.2004.12.004. View

10.

Zhang J, Casiano C, Peng X, Koziol J, Chan E, Tan E . Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003; 12(2):136-43. View

11.

Doyle G, Betz N, Leeds P, Fleisig A, Prokipcak R, Ross J . The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res. 1998; 26(22):5036-44. PMC: 147974. DOI: 10.1093/nar/26.22.5036. View

12.

Eggenschwiler J, Ludwig T, Fisher P, Leighton P, Tilghman S, Efstratiadis A . Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. Genes Dev. 1998; 11(23):3128-42. PMC: 316748. DOI: 10.1101/gad.11.23.3128. View

13.

Soo Hoo L, Zhang J, Chan E . Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene. 2002; 21(32):5006-15. DOI: 10.1038/sj.onc.1205625. View

14.

Imai H, Nakano Y, Kiyosawa K, Tan E . Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer. 1993; 71(1):26-35. DOI: 10.1002/1097-0142(19930101)71:1<26::aid-cncr2820710106>3.0.co;2-n. View

15.

Disis M, Pupa S, Gralow J, Dittadi R, Menard S, Cheever M . High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol. 1997; 15(11):3363-7. DOI: 10.1200/JCO.1997.15.11.3363. View

16.

Soussi T . p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000; 60(7):1777-88. View

17.

Nielsen J, Christiansen J, Johnsen A, Wewer U, Nielsen F . A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999; 19(2):1262-70. PMC: 116055. DOI: 10.1128/MCB.19.2.1262. View

18.

Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G . Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997; 14(22):2729-33. DOI: 10.1038/sj.onc.1201110. View

19.

Tan E . Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest. 2001; 108(10):1411-5. PMC: 209427. DOI: 10.1172/JCI14451. View

20.

Rogler C, Yang D, Rossetti L, Donohoe J, Alt E, Chang C . Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem. 1994; 269(19):13779-84. View